<DOC>
	<DOCNO>NCT00541333</DOCNO>
	<brief_summary>The purpose project investigate eye dry AMD , efficacy safety preventive therapy immunomodulatory substance name copaxone proven safe effective agent neurodegenerative disease , arrest progression well conversion dry AMD wet AMD . The hypothesis immunomodulatory agent copaxone proven neurodegenerative disease may work eye revolutionary may open new avenue preventive treatment disease major cause legal blindness industrial world</brief_summary>
	<brief_title>Weekly Vaccination With Copaxone Potential Therapy Dry Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Dry AMD one eye 2 . Age 50 either gender 3 . Signed informed consent . 1 . Known sensitivity Mannitol Copaxone . 2 . Skin disease active infection skin . 3 . Active fever active treatment infection . 4 . History uncontrolled systemic active disease . 5 . Premenopausal females use reliable birth control . 6 . Sensitivity fluorescein iodine . 7 . Inability comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Dry Age Related Macular Degeneration</keyword>
	<keyword>Dry AMD</keyword>
</DOC>